Podcasts about friedrich schiller university

Send us a textProf. Dr. Niels Riedemann, MD, Ph.D. is Chief Executive Officer and Founder of InflaRx ( https://www.inflarx.de/Home/About-Inflarx/Team~Niels-C.-Riedemann~.html ), a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR inhibitors to the treatment of life-threatening or debilitating inflammatory diseases with high unmet medical need. Prof. Dr. Riedemann has over 15 years of experience in the biotech industry and drug development, as well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx. As physician, Prof. Dr. Riedemann was appointed Vice Director (“Leitender Oberarzt”) of Intensive Care Medicine, and led a 50-bed University ICU unit for over 6 years at Friedrich Schiller University, Jena, Germany until 2015. Before that, he received his board certification as General Surgeon upon completion of his surgical fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received his habilitation (equivalent to Ph.D.) and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral research fellow at the University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg, Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998. Prof. Dr. Riedemann's research has been awarded with several national and international awards. He has received extensive extra-mural funding and published over 60 peer reviewed scientific publications in highly ranked journals. He has served as a member on a Board of Directors and a Scientific Advisory Board of two large scientific governmental funded programs. He currently serves as Co-Chair of the Health Politics working group of Bio-Deutschland and he serves as member of the board of trustees for the German Sepsis Foundation.#NielsRiedemann #InflaRx #Inflammation #ComplementComponent5a  #Sepsis #AcuteRespiratoryDistressSyndrome #Covid #ARDS #GOHIBIC #Vilobelimab #PyodermaGangrenosum #ChronicSpontaneousUrticaria #HidradenitisSuppurativa #Preparedness #BARDA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textIn this episode, April drags herself out of bed while recovering from a wicked case of Influenza A (you might notice her somewhat gravelly vocal quality) to record this episode about an important and timely topic--the language of demagoguery. While we tend to think of it as something politicians and other powerful people use, she discovers to her dismay that we are all capable of being "nascent demagogues" and using this rhetorical technique in our everyday discussions about politics. Hey, let's try not to do that, okay?Episode 37 Show Noteshttps://gordoncstewart.com/2023/12/05/the-language-of-demagoguery-2/Social commentator and blogger Gordon Stewart discusses how language is used for social manipulation, referencing Senator Newt Gingrich.https://feps-europe.eu/powerless-arguments-demagogue-and-populist-language/Robert Feustel is a researcher at Friedrich Schiller University, and this article discusses the difficulty of arguing with someone using demagogic language.https://www.tandfonline.com/doi/full/10.1080/02773945.2019.1610636Skinnell and Murphy's excellent article on the pervasiveness of the language of demagoguery.https://www.mediaethicsmagazine.com/index.php/browse-back-issues/209-spring-2017-vol-29-no-2/3999195-media-rhetoric-and-the-demagoguery-of-the-eliteGood article by rhetorician Patricia Roberts-Miller of the University of Texas at Austin, who also wrote the book Demagoguery and Democracy.https://www.tandfonline.com/doi/full/10.1080/00963402.2024.2388461#abstractI didn't really reference this excellent treatise about the way that demagogues destroy democracy by John Keane, but I highly recommend that you read it anyway.https://research-information.bris.ac.uk/en/publications/demagoguery-technology-and-cognition-addressing-the-threats-to-deStephen Lewandowsky's paper on demagoguery and how it threatens democracy.https://www.historyhit.com/culture/anti-jewish-propaganda-in-nazi-germany/Some examples of how the Nazis used anti-Jewish propaganda to influence German citizens.https://brainapps.io/blog/2025/01/stand-up-against-demagogy-protect/This article contains some very helpful tips about how to recognize and stand up to demagogic rhetoric.

Transcript with time code:  https://cuttingedgehealth.com/wp-ontent/uploads/2024/12/Transcript-45-Dr-Ralf-Oettmeier.pdf This Cutting Edge Health episode features Dr. med Ralf Oettmeier. The title “Dr. med” is commonly used in German-speaking countries in Europe, including Germany, Austria, and Switzerland. It's equivalent to MD in the US. Dr. Oettmeier is medical director of the Alpstein Clinic outside of Zurich. It's at this clinic where they perform INUSpheresis, a cutting-edge detoxification therapy designed to remove waste from plasma. This technique removes environmental toxins, metals, microplastics, pesticides, and inflammatory agents from the blood via a specialized filtration system. Dr. Oettmeier explains the holistic benefits of INUSpheresis for treating chronic illnesses, post-COVID syndrome, and as a preventive measure against cognitive decline, cancer, and heart disease. The therapy, unavailable in the U.S. due to FDA restrictions, complements traditional treatments like chelation but is gentler on the kidneys. Dr. Oettmeier highlights its effectiveness in improving health metrics. This conversation with Dr. Oettmeier underscores the importance of addressing toxins for longevity. Learn how this innovative approach has the potential to help you take charge of your well-being and age gracefully. ***** Dr. med. Ralf Oettmeier is head physician and medical director of the Alpstein Clinic in Gais, Switzerland, an integrative medical practice. Originally trained in conventional medicine at Friedrich Schiller University in Jena, Germany, Dr. Ralf, as he is called by his clients, acquired knowledge from various alternative forms of therapy over the years. He considers the Alpstein Clinic's greatest strength to be successfully bringing together various disciplines of complementary medicine, such as homeopathy and acupuncture. Through the interaction of the individual disciplines, they achieve results that would otherwise never have been possible. One of those therapies is INUSpheresis® where disease-promoting substances and environmental toxins are filtered from your blood. Dr. Oettmeier recently lectured on this at the 14th European Congress of Integrative Medicine. ***** Cutting Edge Health podcast website: https://cuttingedgehealth.com/ Cutting Edge Health Social and YouTube: YouTube channel: youtube.com/@cuttingedgehealthpodcast Instagram - https://instagram.com/cuttingedgehealthpodcast Facebook - https://www.facebook.com/Cutting-Edge-Health-Podcast-with-Jane-Rogers-101036902255756 Please note that the information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Cutting Edge Health podcast, its employees, guests and affiliates assume no liability for the application of the information discussed. Special thanks to Alan and Maria on the Cutting Edge Health team!  

Maybe you have a deep, booming voice. Or perhaps it's light and mellifluous. Some people's voices are honey-smooth while others are as rough as gravel. But why does your voice sound the way it does? CrowdScience listener Hannah in Berlin is training as a teacher and will be using her voice a lot in the classroom in future. She wants to understand more about it: how can she improve the quality of her voice and protect it? And what factors - physical, genetic and environmental - determine the sound of your voice in the first place? Together with presenter Marnie Chesterton, Hannah pays a visit to speech tutor Prof Viola Schmidt at the Ernst Busch University for the Performing Arts in Berlin. Viola and actor Aurelius give us a masterclass in just what your voice can do, as they throw words and sounds to each other across the rehearsal room at a dizzying pace. And Viola gives Hannah a few top tips on using her voice clearly and authentically in the classroom. Hannah's isn't the only voice-related question in this episode. Peter from the Kingdom of Eswatini thinks people there speak more loudly than in other countries, and wonders why. To answer Peter's question we turn to Prof Caleb Everett from the University of Miami. The jury's out on whether people in some countries really do turn up the volume, but Caleb shares evidence of a link between the climate of a particular region and the sound of its native language. And finally, listener Jonathan has an unusual question for Marnie. When listening to CrowdScience, he can't tell whether he's hearing Marnie or fellow presenter Caroline Steel. This got him wondering whether it's common for two people to sound very similar. Marnie gives Caroline a call, and together they set out to discover if your voice really is unique to you. Caroline tracks down a forensic speech scientist - Dr Jess Wormald from the University of York in the UK – while Marnie speaks to Dr Melanie Weirich from the Friedrich Schiller University of Jena in Germany. And both experts agree that Jonathan may be onto something!Presenter: Marnie Chesterton with Caroline Steel Producer: Jeremy Grange Editor: Cathy Edwards Production co-ordinator: Ishmael Soriano Studio Manager: Donald MacDonald

In this episode, we explore the intricate geopolitical dynamics of the South Caucasus, focusing on Georgia and Azerbaijan. Azerbaijan plays a crucial role as a key energy supplier and transit route, connecting Europe and Asia, and its relationship with Georgia is vital for both economic cooperation and security. The discussion highlights how Georgia's pursuit of Western integration is perceived as a choice between Western alignment and Russian influence – an issue central to the upcoming parliamentary elections in the country. We also delve into the EU's role in the region, emphasizing the need for a cohesive strategy that prioritizes peace and stability amid diverse national ambitions. The conversation extends to other regional powers, including Iran, Turkey, and China, examining their influence and interests in the South Caucasus. Both regional actors and the EU must "unlearn" outdated perceptions and adapt to new realities, fostering constructive dialogue and economic cooperation. Guests: Maia Panjikidze is a Georgian diplomat and politician who served as the country's Foreign Minister from 2012 to 2014. She was Georgia's Ambassador to Germany from 2004 to 2007 and to the Netherlands from 2007 to 2010. A PhD in German Studies and a graduate of the Friedrich Schiller University in Jena and Tbilisi State University, she is also a freelance translator and author of works on German language and literature. Panjikidze translates between Georgian and German and has made significant contributions in both fields. Zaur Shiriyev is a nonresident scholar at the Carnegie Russia Eurasia Center. His research focuses on security, conflict-resolution and foreign-policy issues relating to the South Caucasus; energy security and supply routes across that region, southeastern Europe and Central Asia; and on Azerbaijani and Turkish foreign policy. For two decades he has worked in academia and think tanks. He has also actively taken part in expert-level meetings on the Azerbaijan-Armenia peace process. Moderation: Marylia Hushcha, Researcher and Project Manager at the IIP. Recorded on 15 October 2024.

I am thrilled to share my conversation with the renowned sociologist Hartmut Rosa. It was a unique and thought-provoking dialogue delving into the intricacies of modernity, control, and resonance. Rosa touches on various elements, from the role of resonance in a fulfilling life to the necessity of a common good in society, providing an insightful exploration into contemporary socio-political and spiritual issues.  This conversation took place at Princeton Theological Seminary as part of The Church, The Pastor, And Resonance In An Accelerated Age event. The team at The Center for Barth Studies did a fantastic job hosting the event, I am grateful for all the energy they put into it. Hartmut Rosa is professor of sociology at the Institute of Sociology at the Friedrich Schiller University of Jena and director of the Max Weber Center for Advanced Cultural and Social Studies at the University of Erfurt, Germany. He has worked with the New School for Social Research in New York and the universities of Augsburg, Duisburg-Essen and Manheim, among others. Often considered a leading representative of the new critical theory, his research interests include the sociology of time and identity formation. Notable among his publications are Social Acceleration, The Uncontrollability of the World , Resonance: A Sociology of Our Relationship to the World, and his newest book, Democracy Needs Religion. If you want to get an introduction to Rosa's main concepts and how they inspired the gathering at Princeton, you can listen to Andrew Root talk to me here. If you are interested in a deep dive into the work of Hartmut Rosa and Charles Taylor, then check out my class with Dr. Root - Religion & the Spiritual Crisis. _____________________ Join my Substack - Process This! Join our upcoming class - THE RISE OF BONHOEFFER, for a guided tour of Bonhoeffer's life and thought. Come to THEOLOGY BEER CAMP. Follow the podcast, drop a review, send feedback/questions or become a member of the HBC Community. Learn more about your ad choices. Visit megaphone.fm/adchoices

With Torsten Doenst & Philine Fleckenstein, Jena University Hospital, Friedrich Schiller University of Jena - Germany.   Link to paper   Link to editorial

Podcast Description: In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Christhardt Köhler and Achim Schneider to discuss radical vaginal trachelectomy. Prof. Christhardt Köhler is a highly accomplished gynecologist and obstetrician specializing in oncological gynecology. He is the Chief Physician of the Department of Gynecology at Asklepios Hospital Altona Hamburg and has won the Briker Award and the Robert B. Hunt Endowed Award. Dr. Kohler is a member of several professional associations, including the German Society for Gynecology and Obstetrics. His expertise is recognized worldwide, and he is listed in the FOCUS top list of physicians for gynecological operations and tumors. He has 1381 scientific publications focusing on spinal muscular atrophy, cervical cancer, and innovative gynecological surgery approaches. Achim Schneider, born on September 17, 1950, in Augsburg, is a distinguished German gynecologist and obstetrician. He earned his doctorate in 1975 and has since made significant contributions to the field, including pioneering new laparoscopic surgical techniques in gynecological oncology in Germany. Schneider held prestigious professorships at the Friedrich Schiller University in Jena and the Charité in Berlin. He has focused on the diagnosis and treatment of genital neoplasms, HPV-associated ano-genital neoplasms, and fertility-preserving surgery for cervical cancer patients. Currently, he heads the dysplasia consultation at the Medical Care Center in Berlin, continuing his impactful work in minimally invasive procedures and cancer prevention. Highlights: Radical vaginal trachelectomy is a fertility-preserving treatment for early cervical cancer, but large studies on its outcomes are lacking. In a study of 471 patients (median age 33), 62% sought pregnancy with a 73% success rate, and 46% experienced pre-term delivery; recurrences occurred in 3.4% of cases, with a 2.1% mortality rate. The study confirms the oncologic safety of the procedure and suggests that high pre-term delivery rates may be due to cervical volume loss, providing a benchmark for future surgical modifications

Join us as we explore the concept of compassion fatigue from a fresh perspective. We take a closer look at the underlying mechanisms behind the terms commonly used when we talk about sustainable careers. While empathy and compassion are often used interchangeably, they are actually distinct concepts, and it's not just a matter of semantics - it's a matter of neurology, which has practical implications for you, your career, and your happiness.  Dr Olga Klimecki is a neuroscientist, psychologist, and certified mindfulness and meditation teacher. She holds a PhD from the University of Zurich in Switzerland and is currently a lecturer and senior researcher at the Friedrich Schiller University of Jena in Germany. Her research focuses on advancing sustainable development goals related to peacebuilding, conflict resolution, socio-emotional education, and overall well-being. With over 70 publications to her name, Dr Klimecki's work on neural plasticity and conflict resolution has earned her prestigious international awards, grants, and fellowships. Additionally, she runs her own consulting, training, and research company to implement evidence-based strategies in various organisations, start-ups, and companies. During this conversation, we explore the nuances of empathy and compassion, highlighting their differences and learning why empathy can sometimes have negative consequences, and the term "compassion fatigue" might be a misnomer. We also learn how we can practically apply of this knowledge, explaining how you can rewire your brain to experience the hard things we sometimes need to do as positive experiences, rather than something painful and draining.  Topic list: 6:02 Empathy and compassion. Are they the same thing? 13:52 The connection between empathy and prosocial behaviour. 17:39 Can we really change the way we empathise with others? 20:59 fMRI results from training compassionate and empathetic responses. 27:17 If compassion is good, then where does the term compassion fatigue come from? 29:13 Why empathy first, compassion next? 30:36 It's not the compassion causing your fatigue... you are just fatigued. 32:16 How do we train compassion? Olga's tips to train your brain. 39:03 The hardest part of meditation training. 41:39 Put out the welcome mat and notice your judgements. 44:34 Between a stimulus and a response, there is always a space. 47:03 Reflex responses and training ourselves out of them. Join our community of Vet Vault Nerds to lift your clinical game and get your groove back with our up to date easy-to-consume clinical episodes at ⁠⁠⁠⁠vvn.supercast.com. ⁠⁠⁠⁠ Visit ⁠⁠⁠⁠thevetvault.com⁠⁠⁠⁠ for the show notes and resources for this episode, and connect with us through our online ⁠⁠⁠⁠Vet Vault Network for episode highlights, discussions, questions and support. Join us at ⁠⁠⁠⁠Vets on Tour in Wanaka, New Zealand⁠⁠⁠⁠ on 13 - 18 August 2023 for great CE, live podcasting and snow... lots of snow! Come help us create some live clinical content at ⁠IVECSS '23⁠ in Denver, Colorado from 7-11 September. Get up and running (or working!) with a 10% discount for Tarkine shoes, the official shoe of the Vet Vault. (discount automatically applied at checkout using this link). Olga's Research Article - Empathy and Compassion --- Send in a voice message: https://podcasters.spotify.com/pod/show/vet-vault/message

Metahumanist philosopher Stefan Lorenz Sorgner shares his thoughts on the debates surrounding contemporary transhumanism, the possibility of immortality achieved through mind-uploading, and the ethical issues associated with gene editing, digital data collection, and life extension. Prof. Stefan Lorenz Sorgner teaches philosophy at John Cabot University in Rome, whereby he particularly promotes the emerging field of posthuman studies. He is also Director and Co-founder of the Beyond Humanism Network, Fellow at the Institute for Ethics and Emerging Technologies (IEET), Research Fellow at the Ewha Institute for the Humanities at Ewha Womans University in Seoul, and Visting Fellow at the Ethics Centre of the Friedrich-Schiller-University in Jena, where he was also Visiting Prof. during the summer of 2016. He studied philosophy at King's College/University of London (BA), the University of Durham (MA by thesis; examiners: David E. Cooper, Durham ; David Owen, Southampton), the University of Giessen and the University of Jena (Dr. phil.; examiners: Wolfgang Welsch, Jena; Gianni Vattimo, Turin). In recent years, he taught at the Universities of Jena (Germany), Erfurt (Germany), Klagenfurt (Austria) Ewha Womans University in Seoul (South Korea) and Erlangen-Nürnberg (Germany). His main fields of research are Nietzsche, the philosophy of music, bioethics and meta-, post- and transhumanism. Find out more: futurespodcast.net CREDITS Produced by FUTURES Podcast Recorded, Mixed & Edited by Luke Robert Mason FOLLOW Twitter: twitter.com/futurespodcast Facebook: facebook.com/futurespodcast Instagram: instagram.com/futurespodcast

This week, join authors Steven Lubitz and Associate Editor Mark Link as they discuss the article "Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial." Dr. Carolyn Lam:             Welcome to Circulation on the Run, your weekly podcast, summary and backstage pass of the journal and its editors. We're your co-hosts. I'm Dr.  Carolyn Nam, Associate Editor from the National Heart Center in Duke National University of Singapore. Dr. Greg Hundley:           And I'm Dr. Greg Huntley, Associate Editor, Director of the Pauley Heart Center from VCU Health in Richmond, Virginia. Dr. Carolyn Lam:             Well, guess what we have for the featured discussion today, Greg. It's about screening for atrial fibrillation in older adults at primary care visits. Very, very important topic. And what we'll be looking at is the vital AF randomized control trial. Ooh, we're going to keep everyone in suspense here as we carry on and discuss today's papers. Can I start? Dr. Greg Hundley:           Absolutely. Dr. Carolyn Lam:             Alright. This first paper is about infective endocarditis. Now, we know that cardiac surgery often represents the only treatment option in patients with infective endocarditis. However, infective endocarditis surgery may lead to a sudden release of inflammatory mediators, which is associated with the severity of postoperative organ dysfunction. So, authors Dr. Doesnst from Friedrich Schiller University of Jena in Germany, and colleagues, decided to investigate the impact of hemo absorption during infective endocarditis surgery on post-operative organ dysfunction. This multicenter, randomized, non-blinded controlled trial assigned 288 patients undergoing cardiac surgery for infective endocarditis to hemo absorption, which is integration of cytosorb to the cardiopulmonary bypass or control. The primary outcome was defined as the difference between the mean total postoperative sequential organ failure assessment score, calculated maximally to the ninth postoperative day, and the difference with the basal score. Secondary outcomes were 30 day mortality, durations of mechanical ventilation, basal presser and renal replacement therapy. Cytokines were also measured in the first 50 patients. Dr. Greg Hundley:           Interesting study, Carolyn. Wow. So, what are the results? Dr. Carolyn Lam:             Yes, this trial involved a lot of work and results showed, however, that there was a failure to demonstrate a reduction in postoperative organ dysfunction, 30 day mortality, or any of the clinically relevant secondary outcomes through intraoperative hemo absorption. Although hemo absorption reduced plasma cytokines at the end of cardiopulmonary bypass, there was no difference in any of the clinically relevant outcomes. Dr. Greg Hundley:           Great description, Carolyn. Well, my first paper comes to us from the world of preclinical science. And Carolyn, the ascending thoracic aorta, site of aneurysm formation, is populated by a mosaic of medial and adventitial cells that are embryonically derived from either the second heart field, or the cardiac neural crest. Second heart field derives cells, populate areas that coincide with the spatial specificity of thoracic aortopathies that are often associated with aneurysms. And so, this study, led by Dr. Alan Daugherty, from the University of Kentucky. Its purpose was to determine whether and how second heart field derived cells contribute to as sending aortopathies. Dr. Carolyn Lam:             Wow, an important topic, Greg. What did the authors find? Dr. Greg Hundley:           Okay. So, Carolyn, first, ascending aortic pathologies were examined in patients with sporadic thoracic aortopathies and angiotensin 2 infused mice. And so, the investigators found several things. First, second heart field derived smooth muscle cells and fibroblasts associate with angiotensin 2 induced aortic pathologies. Second, angiotensin 2 induced a distinct fibroblast sub-cluster that was less abundant for messenger RNAs related to major extracellular components and TGF beta-ligands and receptors, but more abundant for proliferative genes. Third, TGFBR2 deletion in second heart field derived cells were embryonically lethal, with significant dilatation of the outflow tract in the mice. And finally, second heart field specific deletion of LRP1 led to aortic pathologies in mice, supporting the importance of second heart field derived cells in maintaining ascending aortic wall integrity. Dr. Carolyn Lam:             Wow. Could you just sum up the clinical implications for us, Greg? Dr. Greg Hundley:           Well, Carolyn, I knew you were going to ask me that. So, these results indicate that heterogeneity of the embryonic origins of smooth muscle cells and fibroblasts contributes to complex mechanisms of vasculopathy formation, which should be considered when investigating the pathogenesis of thoracic aortopathies. Dr. Carolyn Lam:             Wow, thanks Greg. Well, my next study is also a translational study, and this one provides a deeper understanding of insulin regulation of cholesterol metabolism, and its disruption in type one diabetes. So, this is from Dr. Biddinger from Children's Hospital Boston and colleagues. In order to define the mechanisms by which insulin controls plasma cholesterol levels, the authors knocked down the insulin receptor, FOXO1, and the key bioacid synthesis enzyme, CYP8B1, in mice. They measured bioacid composition, cholesterol absorption, and plasma cholesterol. In parallel, they measured markers of cholesterol absorption and synthesis in humans with type one diabetes treated with ezetimibe and statins in a double blind crossover study. Dr. Greg Hundley:           Oh, wow, Carolyn. So, experiments in both animal models and in human subjects. So, what did they find? Dr. Carolyn Lam:             Insulin, by inhibiting FOXO1 in the liver, reduces 12 alpha hydroxylated bio acids, reduces cholesterol absorption and reduces plasma cholesterol levels. Thus, type one diabetes leads to a unique set of derangement in cholesterol metabolism with increased absorption rather than increased synthesis. These derangements are reversed by ezetemibe, which is a cholesterol absorption inhibitor, but not simvastatin, which is a cholesterol emphasis inhibitor. So, taken together, these data suggest that a personalized approach to lipid lowering in type one diabetes may be more effective, and highlight the need for further studies specifically in this group of patients. Dr. Greg Hundley:           Nice, Carolyn. Well, we've got some other really interesting or articles in the issue. And first, from the mail bag, there's a Research Letter from Professor Bers, entitled "Empagliflozin Reverses Late Sodium Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murray Model of Heart Failure with Preserved Ejection Fraction." Carolyn, there's another research letter from Professor Shu entitled, "Activation Of INKY Cells at the Maternal Fetal Interface that Predisposes Offspring to Cardiac Injury." Also, there's a really nice, in depth article entitled, "Takasubo Syndrome Pathophysiology Emerging in Concepts and Clinical Implications." And it's from Dr. Trisha Singh. Dr. Carolyn Lam:             Nice. We also have an ECG challenge by Dr. Mugnai on “A Tachycardia in Disguise” and a Perspective piece by Dr. Alexander on “Equipoise in Clinical Trials: Enough Uncertainty [but] in Whose Opinion?” Isn't that interesting? Wow, thanks, Greg. Now, though, let's go on to this super exciting feature discussion on screening for atrial fibrillation in older adults' primary care. Dr. Greg Hundley:           You bet. Well, listeners, we are here for the feature discussion, now, on this March 29th issue. And we have with us Dr. Steve Lubitz, from Mass General and Boston, and our own associate editor, Dr. Mark Link, from University of Texas Southwestern Medical Center in Dallas, Texas. Welcome, gentlemen. So, Steve, we're going to start with you. Can you describe for us some of the background information that went into the construct of your study, and then what was the hypothesis that you wanted to address? Dr. Steven Lubitz:            Sure. Well, thanks for the opportunity to talk with you today about our work. So, as we know, AFib is a common and more bitter arrhythmia. And the first manifestation of AFib can be stroke in a substantial number of individuals. Strokes from atrial fibrillation or debilitating, but they can be prevented using oral anticoagulants if we know who has atrial fibrillation. But atrial fibrillation can be a symptomatic and it's possible, therefore, that screening pre-AFib could lead to new diagnoses and ultimately improve outcome by enabling stroke prevention. Point of care screening for AFib has been embraced by some guidelines for individuals age 65 or older, such as those in Europe, and mobile technology has now evolved and enables rapid mask screening using handheld ECGs, single lead ECGs, which obviates the need and expense of performing 12-lead ECGs to screen for AFib. Nevertheless, though, some guidelines have suggested that data are insufficient to recommend screening AFib using ECGs, such as those from the United States Preventative Services Task Force. We tested whether screening individuals age 65 or older at the time of a primary care clinic visit using a single lead ECG would lead to an increased rate of detection of AFib in contemporary United States practices. Dr. Greg Hundley:           Very nice. And so, maybe describe for us this task force, and also what was your study design and, again, your study population? Dr. Steven Lubitz:            Sure. So, specifically our study design, we performed a cluster randomized control trial in which primary care practice clinics were randomized to the screening intervention or to usual care, and patients aged 65 or older arriving for a primary care visit with their provider were eligible for participation. Patients were offered screening by practiced medical assistants at the time of their vital sign assessments, and screening was performed, if they consented, within a live core cardio mobile single ECG device, which was affixed to an iPad and stationed in the clinic. The results of the screening were made available to the providers at the time of the visit, and then the provider was able to make any and all decisions about subsequent management, confirmation or treatment. The primary outcome was a new diagnosis of Afib made in the medical record at one year following the start of the screening intervention, and the outcome was ascertained using the electronic health record and then manually adjudicated. We powered the study to detect a difference of nearly 0.5% in the rate of atrial fibrillation diagnoses at 12 months between the screening and usual care arms. Dr. Greg Hundley:           And how many patients did you enroll? And then what were your study results? Dr. Steven Lubitz:            Well, eight practices were randomized to the screening arm and eight practices to the usual care arm. And in total, that equated to about 15000 patients without a history of atrial fibrillation in the screening arm and 15000 patients in the control arm without a history of atrial fibrillation. The mean age was about 74, about 60% were female, 82% were white. And the mean chad-vad score was 3.4. We observed several main findings. The first is that, of the individuals in the screening arm, 91% were screened at least once. And this is the largest point of care screening study to date. The rate of screening in the intervention arm was substantially greater than any other contemporary trial, point of care, single ECG screening. We think that high rate of compliance with the intervention reflects patient enthusiasm for screening and a widespread feasibility of incorporating single ECGs into the routine vital sign practice workflow. Secondly, the primary endpoint, however, incidence of new AFib diagnoses at 12 months, was 1.72% in the screening arm, and 1.59% in the usual care arm, which equates to a risk difference of .13%. That was not statistically significant in the overall sample. We observed a substantial difference in new AFib diagnoses among those aged 85 or older in pre-specified subgroup analyses, 5.56% in the screening arm and 3.76% in usual care arm, which corresponds to a risk difference of 1.8%, where a number needed a screen of about 55, raising the possibility that point of care single ECG screening among the oldest and highest risk individuals might be effective. But this finding warrants future study. Third, we observed a shift in the location of diagnosis. So, they fit with a higher likelihood of diagnosis at a primary care practice encounter in the screening arm, as compared to the usual care arm, which is as expected. And the implications on downstream management pathways, cost of care, other downstream work flows is unknown at the moment. And lastly, we observed it in anticoagulation use was high, even among those with AFib diagnosed in the screening arm, which is a reassuring finding, suggesting that clinicians recognized that AF detected using this single lead point of care screening is likely to represent high burden, persistent AF that carries a substantial risk of stroke. Dr. Greg Hundley:           Very nice. Well, Mark, I know you review many papers for us here at Circulation. What attracted you to this particular paper? Dr. Mark Link:    This issue of point of care screening for AFib is a very hot topic. We all know that clinically diagnosed AFib carries with it a high risk of stroke, but what we don't know is incidentally found Afib, or nonclinically found Afib, what does that mean? This was one of the largest, if not actually the largest, study of point of care screening. And the i-cors are a very accurate device, or reasonably accurate device. So, we thought it's an important contribution to the literature. I think it surprised the authors, as well as us, there wasn't a difference in the diagnosis of AFib between the two arms. I think all of us would've expected to see that. But we're still learning a lot about point of care screening, and we're not to the point where we know what to do yet. Dr. Greg Hundley:           And Mark, what are some of your thought? Steve raised the point that, in that subgroup, greater than age 85, any additional insights there? Dr. Mark Link:    Yeah. I think that, if you can enrich your group with people that are more likely to have AFib, and the older you get, the more likely you are to have AFib, you are more likely to find Afib. But then treating people over age 85 also becomes a little bit riskier, with both anticoagulants and antirhythmic drugs and ablation. Dr. Greg Hundley:           Great points. Well, Steve, coming back to you, what do you see as the next study to be performed, really, in this sphere of research? Dr. Steven Lubitz:            Thanks. I think I proposed two additional lines of inquiry. At first, I think our hypothesis generating observation to the point of care screening with a single EDCG can lead to higher rates of AFib detection among the oldest individuals, age 85 or older, with a small number needed to screen warrants, replication, and the downstream implications of that on stroke and bleeding merit further evaluation. I think secondly, given the proliferation of wearable technology, future studies should examine the effectiveness of detecting perccismal atrial fibrillation for preventing downstream adverse events, including stroke. This point of care screening is likely to detect the highest burden persistent forms of atrial fibrillation in contrast to some of the wearable technology, like consumer wearable technology, that might detect paroxysmal atrial fibrillation, more commonly. Dr. Greg Hundley:           Ah, great point. And Mark, how about you? Anything to add? What future study do you see needs to be performed in this space? Dr. Mark Link:    It's clear from a number of studies that the longer that you monitor someone, the more likely you are to get a diagnosis of AFib. And that's pretty clear. This was a 30 second monitor. We have a number of studies that have shown two week and ILS monitoring is far more likely to get a diagnosis of AFib. But what we don't know is, if making that diagnosis of AFib makes any difference on ultimate outcomes. That's the studies that we need to see, is does treatment of incidentally found AFib improve clinical care. Dr. Greg Hundley:           Very good. Well, listeners, we want to thank Dr. Steve Lubitz from Mass General in Boston, and also Dr. Mark Link from UT Southwestern in Dallas, bringing us results from this study indicating that screening for atrial fibrillation using a single lead EKG at a primary care visit did not affect new atrial fibrillation diagnoses among those that were aged 65 years or older. There was, perhaps, a difference in those aged greater than 85 years, but more research is to come in that space. And, of course, looking for peroxisomal AFib with handheld devices is another area you yet to be investigated. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week, On the Run. Dr. Greg Hundley:           This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 15 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies. Prior to joining Ribon, Dr. Keilhack was Senior Director of Biology at Epizyme where, among other responsibilities, she was the project leader for the company's EZH2 inhibitor program, tazemetostat, which was FDA-approved in 2020 as Tazverik®. Before that, she was a research fellow at Merck and the biology project lead for the company's clinical stage AKT inhibitor, MK-2206. Dr. Keilhack received her Ph.D. in Biochemistry at Friedrich Schiller University of Jena (Germany) and completed postdoctoral training at the Harvard Medical School. She earned a B.S. in Biochemistry at Martin Luther University of Halle-Wittenberg (Germany).

The UK government used a statistical algorithm to alter children’s grades for exams missed in lockdown. But critics have argued that this algorithm, which used old data on school performance, unfairly stigmatised pupils from poorer backgrounds. Stian Westlake from Britain’s Royal Statistical Society speaks to Gareth and Bill about the challenges of creating such an algorithm and where the government went wrong. The Language of Trolls What is it like to work as a Twitter troll? Researcher Sergei Monakhov, from the Friedrich Schiller University in Germany, used this question to discover how the language used by trolls is different from that used by regular users. He discusses how these patterns can be used to spot troll’s social media posts much more quickly. Saving lives with data in Africa A digital tool-kit has been designed to help governments and health organisations in Africa tackle the spread of Covid-19. Dr. Sema Sgaier, executive director of the Surgo Foundation describes the Africa Covid-19 Community Vulnerability Index, which maps regional data on health, economic, and social robustness to find where Covid might hit hardest. (Photo: Student protesters hold up banners. Credit: Andrew Milligan/PA) Producer: Julian Siddle

To tell us about Immunology, we are joined by Shivalee Duduskar, a trained Biotechnologist. She is pursuing her Doctorate in Immunology from Friedrich Schiller University, Jena, Germany. She is going to take us through her journey of getting into the field of Immunology. Following her passion for art, Shivalee has found a way to bridge the gap between science and art with her scientific illustration service - Biotale Illustration. It helps scientists, researchers and biotech companies demonstrate their offerings in the form of art.Listen to know more about Shivalee's venture!Connect with Shivalee on socialInstagram @ShivaleeConnect with me on socialInstagram @womendecodeTwitter @womendecode

In this episode we learned a few things about Jena. As always Steven got to read some German sentences about it and tried to translate them into English. Here are the sentences again: Jena ist eine Stadt in der Mitte von Deutschland. Jena is a city in the middle of Germany. Jena hat über 100.000 Einwohner und ist die zweitgrößte Stadt in Thüringen. Jena has over 100,000 inhabitants and is the second largest city in Thuringia. 1558 wurde die Friedrich-Schiller-Universität Jena gegründet. In 1558 the Friedrich Schiller University of Jena was founded. Sie ist nun die größte Universität Thüringens. It is now the largest university in Thuringia. Sie ist benannt nach dem Dichter Friedrich Schiller, der in Jena Professor für Geschichte war. It is named after the poet Friedrich Schiller, who was a professor of history in Jena. Am 17. November 1846 eröffnete Carl Zeiss eine Mechanikerwerkstatt. On November 17, 1846, Carl Zeiss opened a mechanic's workshop. Heute stellt das Unternehmen nicht nur Objektive, Mikroskope, Brillengläser, Spiegel und Kameras her, sondern auch Güter für die Medizin oder Anlagen zum Umweltschutz. Today, the company not only manufactures lenses, microscopes, spectacle lenses, mirrors and cameras, but also goods for medicine and equipment for environmental protection. In Jena gibt es einen Kaninchensportverein. There is a rabbit sports club in Jena.

In this episode I talk Stefan Lorenz Sorgner. Stefan teaches philosophy at John Cabot University in Rome. He is director and co-founder of the Beyond Humanism Network, Fellow at the Institute for Ethics and Emerging Technologies (IEET), Research Fellow at the Ewha Institute for the Humanities at Ewha Woman's University in Seoul, and Visiting Fellow at the Ethics Centre of the Friedrich-Schiller-University in Jena. His main fields of research are Nietzsche, the philosophy of music, bioethics and meta-, post- and transhumanism. We talk about his book Übermensch: Plädoyer Für Einen Nietzscheanischen Transhumanismus (Schwabe, 2019) John Danaher is a lecturer the National University of Ireland, Galway. He is also the host of the wonderful podcast Philosophical Disquisitions. You can find it here on Apple Podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode I talk Stefan Lorenz Sorgner. Stefan teaches philosophy at John Cabot University in Rome. He is director and co-founder of the Beyond Humanism Network, Fellow at the Institute for Ethics and Emerging Technologies (IEET), Research Fellow at the Ewha Institute for the Humanities at Ewha Woman's University in Seoul, and Visiting Fellow at the Ethics Centre of the Friedrich-Schiller-University in Jena. His main fields of research are Nietzsche, the philosophy of music, bioethics and meta-, post- and transhumanism. We talk about his book Übermensch: Plädoyer Für Einen Nietzscheanischen Transhumanismus (Schwabe, 2019) John Danaher is a lecturer the National University of Ireland, Galway. He is also the host of the wonderful podcast Philosophical Disquisitions. You can find it here on Apple Podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode I talk Stefan Lorenz Sorgner. Stefan teaches philosophy at John Cabot University in Rome. He is director and co-founder of the Beyond Humanism Network, Fellow at the Institute for Ethics and Emerging Technologies (IEET), Research Fellow at the Ewha Institute for the Humanities at Ewha Woman's University in Seoul, and Visiting Fellow at the Ethics Centre of the Friedrich-Schiller-University in Jena. His main fields of research are Nietzsche, the philosophy of music, bioethics and meta-, post- and transhumanism. We talk about his book Übermensch: Plädoyer Für Einen Nietzscheanischen Transhumanismus (Schwabe, 2019) John Danaher is a lecturer the National University of Ireland, Galway. He is also the host of the wonderful podcast Philosophical Disquisitions. You can find it here on Apple Podcasts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Read the full working paper: https://growthlab.cid.harvard.edu/publications/you-get-what-you-pay-sources-and-consequences-public-sector-premium-albaniaLearn more about The Growth Lab: www.growthlab.cid.harvard.eduAbout Ljubica Nedelkoska: Ljubica Nedelkoska joined the Center for International Development's Growth Lab as a Visiting Scholar in 2012 and as a Research Fellow in 2013.Before joining the CID, she worked as a post-doctoral researcher and a coordinator of the Economics of Innovation Research Group in Jena, and as a research fellow at the Zeppelin University, both in Germany.Her research area is empirical labor economics, with focus on human capital, human mobility, migration and diasporas, and skill-technology relations. By studying these topics, she aims to understand how economies change their skill portfolios through the processes of on-the-job learning, interacting with technologies, and formal education and training; and how these changes transform the countries’ levels of productivity and development. She is also interested in economic policy and has participated in several economic policy projects in Albania, Sri Lanka, Germany, the Netherlands and Sweden.She holds a PhD in Economics of Innovation from the Friedrich-Schiller-University in Jena, Germany and a Master's Degree in Public Administration from the Appalachian State University, North Carolina.

In this episode I talk Stefan Lorenz Sorgner. Stefan teaches philosophy at John Cabot University in Rome. He is director and co-founder of the Beyond Humanism Network, Fellow at the Institute for Ethics and Emerging Technologies (IEET), Research Fellow at the Ewha Institute for the Humanities at Ewha Womans University in Seoul, and Visting Fellow at the Ethics Centre of the Friedrich-Schiller-University in Jena. His main fields of research are Nietzsche, the philosophy of music, bioethics and meta-, post- and transhumanism. We talk about his case for a Nietzschean form of transhumanism.You can download the episode here or listen below. You can also subscribe to the podcast on iTunes, Stitcher and a variety of other podcasting apps (the RSS feed is here). Show Notes0:00 - Introduction2:12 - Recent commentary on Stefan's book Ubermensch3:41 - Understanding transhumanism - getting away from the "humanism on steroids" ideal10:33 - Transhumanism as an attitude of experimentation and not a destination?13:34 - Have we always been transhumanists?16:51 - Understanding Nietzsche22:30 - The Will to Power in Nietzschean philosophy26:41 - How to understand "power" in Nietzschean terms30:40 - The importance of perspectivalism and the abandonment of universal truth36:40 - Is it possible for a Nietzschean to consistently deny absolute truth?39:55 - The idea of the Ubermensch (Overhuman)45:48 - Making the case for a Nietzschean form of transhumanism51:00 - What about the negative associations of Nietzsche?1:02:17 - The problem of moral relativism for transhumanistsRelevant LinksStefan's homepageThe Ubermensch: A Plea for a Nietzschean Transhumanism - Stefan's new book (in German)Posthumanism and Transhumanism: An Introduction - edited by Stefan and Robert Ranisch"Nietzsche, the Overhuman and Tranhumanism" by Stefan (open access)"Beyond Humanism: Reflections on Trans and Post-humanism" by Stefan (a response to critics of the previous article)Nietzsche at the Stanford Encyclopedia of Philosophy #mc_embed_signup{background:#fff; clear:left; font:14px Helvetica,Arial,sans-serif; } /* Add your own MailChimp form style overrides in your site stylesheet or in this style block. We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */ Subscribe to the newsletter

CID Research Assistant Sehar Noor interviews Ljubica Nedelkoska, Research Fellow at CID, who discusses the Growth Lab project in Sri Lanka and more specifically her research findings titled “Does Sri Lanka Need More University Graduates?” // www.srilanka.growthlab.cid.harvard.edu // Interview recorded on May 11th, 2018. About Ljubica Nedelkoska: Ljubica Nedelkoska joined the Center for International Development's Growth Lab as a Visiting Scholar in 2012 and as a Research Fellow in 2013. Before joining the CID, she worked as a post-doctoral researcher and a coordinator of the Economics of Innovation Research Group in Jena, and as a research fellow at the Zeppelin University, both in Germany. Her research area is empirical labor economics, with focus on human capital, human mobility, migration and diasporas, and skill-technology relations. By studying these topics, she aims to understand how economies change their skill portfolios through the processes of on-the-job learning, interacting with technologies, and formal education and training; and how these changes transform the countries’ levels of productivity and development. She is also interested in economic policy and has participated in several economic policy projects in Albania, Sri Lanka, Germany, the Netherlands and Sweden. She holds a PhD in Economics of Innovation from the Friedrich-Schiller-University in Jena, Germany and a Master's Degree in Public Administration from the Appalachian State University, North Carolina.

CID Research Assistant Sehar Noor interviews Ljubica Nedelkoska, Growth Lab research fellow at the Center for International Development at Harvard University. Ljubica presented her recently published a paper on the impact of return migration on wages and employment on Albania: http://growthlab.cid.harvard.edu/publications/welcome-home-crisis-effects-return-migration-non-migrants-wages-and Interview recorded on February 24th, 2017. About the speaker: Ljubica's research focuses on human capital, migration, lifelong learning, capital-labor relations and structural transformation. She works at the intersection of research and policy, and has contributed to several such projects in Albania, Sri Lanka, the Netherlands, Sweden, and Germany. She holds a PhD in Economics of Innovation from the Friedrich Schiller University, Germany and a Master’s Degree in Public Administration from the Appalachian State University, North Carolina. Before joining CID, Ljubica worked as a post-doctoral researcher and a coordinator of the Research Group “Economics of Innovation” at the Friedrich Schiller University and as a research fellow at the Zeppelin University in Germany.

Institute of Commonwealth Studies, James-Emmanuel Wanki, University of Limerick, Professor Manuel Fröhlich, Friedrich-Schiller-University,Dr Henning Melber, Dag Hammarskjöld Foundation

Institute of Commonwealth Studies, James-Emmanuel Wanki, University of Limerick, Professor Manuel Fröhlich, Friedrich-Schiller-University,Dr Henning Melber, Dag Hammarskjöld Foundation